



Database Establishment of Ketogenic Diet Clinic in Ain Shams University Children's Hospital

Thesis

*Submitted for Partial Fulfillment
of Master Degree in **Pediatrics***

By

Wafaa Mostafa Abdelwahab Shokair

M.B.B.Ch, Ain Shams University (2009)

Under Supervision of

Prof. Omnia Fathy Elrashidy

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Prof. May Fouad Nassar

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Dr. Yasmin Gamal Abdo El-Gendy

Assistant Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Faculty of Medicine - Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَّانِكَ لَا نَعْلَمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Omnia Fathy Elrashidy**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. May Fouad Nassar**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Yasmin Gamal Abdo El-Gendy**, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

I would like to thank our patients and their families and my colleagues who helped us in this study

Wafaa Mostafa Abdelwahab Shokair

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iv
List of Abbreviations	vii
Introduction	- 1 -
Aim of the Work	4
Review of Literature	
Nutrition Clinic Information Program	5
Ketogenic Diet	19
Epilepsy	43
patients and Methods	65
Results	78
Discussion	108
Summary	118
Conclusion	122
Recommendations	123
References	124
Appendices	I
Arabic summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Epilepsy syndromes and some conditions in which the KD therapies has been reported probable benefit.....	32
Table (2):	Epilepsy syndromes and some conditions in which the KD therapies has been reported possible benefit.....	33
Table (3):	Absolute contraindications for the use of KD therapies.	34
Table (4):	Relative contraindications for the use of KD therapies.	34
Table (5):	Laboratory evaluations	36
Table (6):	Side effects of Ketogenic diet.....	42
Table (7):	Changes in seizure type classification from 1981 to 2017	49
Table (8):	Electroclinical syndromes and other epilepsies.....	51
Table (9):	A proposed diagnostic scheme for people with epileptic seizures and with epilepsy	54
Table (10):	Efficacy spectrum of currently available antiepileptic drugs (AEDS).....	58
Table (11):	Factors to be considered in the selection of an antiepileptic durg	61
Table (12):	Demographic data of the sex, address, mode of delivery, gestational age, consanguinity and postnatal history of the studied patients:	78

Table (13):	Description of the age of onset of convulsions	83
Table (14):	Description of types of seizures among patients	84
Table (15):	Description of duration of KD.....	85
Table (16):	Comparison of weight, height, BMI, Z score for weight, Z score for height, Z score for BMI before and after KD.....	85
Table (17):	Initial and follow up values of cholesterol, high density lipoproteins (HDL), low density lipoproteins (LDL) and triglycerides	88
Table (18):	Description of acetone and random blood sugar in the study patient.....	89
Table (19):	Diagnosis of the patient at presentation.....	90
Table (20):	Demographic data of family history the studied patients and demography of the patients at October 2019	92
Table (21):	The number of patients regularly following up in ketoclinic since its start in 2013 till 2019	93
Table (22):	Description of Compliance of the KD patients.....	95
Table (23):	Description of the patient still following or stopped KD and their compliance.	96
Table (24):	The compliance pattern of the patients during the last 6 years:.....	98
Table (25):	Frequency of complications of KD among patients	100

Table (26):	Comparison between the adaptive behavior of our patients before and after KD by using vineland test	102
Table (27):	Comparison between the adaptive behavior of our patients before and after KD by using vineland test.	102
Table (28):	Comparison of the frequency of convulsions before KD and after 3 months, 6 months, 12 months, 24 months and 36 months of KD.....	104
Table (29):	Comparison of severity of seizure according to Chalfont Score before and after KD	106

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Description of Patient data (name, sex, age and code number).....	9
Figure (2):	Description of Patient present history	10
Figure (3):	Description of Patient medical data.....	11
Figure (4):	Description of patient medical file (complains)	12
Figure (5):	Description of patient medical file (present history)	13
Figure (6):	Description of patient medical file (general history)	14
Figure (7):	Description of patient medical file(laboratory investigations and imaging)	15
Figure (8):	Description of Patient statistical report	16
Figure (9):	Description of Patient statistical report	17
Figure (10):	Description of Patient statistical report	18
Figure (11):	Formation of ketone bodies	20
Figure (12):	Structure of GABA	22
Figure 13:	Metabolic modifications of glutamate and GABA synthesis	24
Figure 14:	Potential pathways through which polyunsaturated fatty acids (PUFAs) may limit hyperexcitability in the brain	26
Figure 15:	ILAE classification of seizure types expanded form	48
Figure 16:	Framework for classification of the epilepsies.....	50

Figure 17:	General principles in the pharmacological treatment of epilepsy.....	60
Figure 18:	Description of the sex of the patients.	79
Figure 19:	Description of the address of the patients.....	79
Figure 20:	Description of the mode of delivery of the patients.....	80
Figure 21:	Description of the gestational age of the patients.....	80
Figure 22:	Description of the consanguinity of the patients.....	81
Figure 23:	Description of the post natal history of the patients.....	81
Figure 24:	Description of the family history of the patients.....	82
Figure 25:	Description of the age of onset of convulsions:	83
Figure 26:	Description of types of seizures among patients.....	84
Figure 27:	Comparison of weight before and after KD.	86
Figure 28:	Comparison of height before and after KD.	86
Figure 29:	Comparison of Z score for weight, before and after KD.....	87
Figure 30:	Comparison of Z score for height before and after KD.....	87
Figure 31:	Initial and follow up values of cholesterol, high density lipoproteins (HDL), low density lipoproteins (LDL) and triglycerides.	89
Figure 32:	The diagnosis of the patient at presentation	91

Figure 33:	Demography of the patients in 2019.....	92
Figure 34:	The number of patients regularly following up in ketoclinic since its start in 2013 till 2019:	94
Figure 35:	Description of the rate of change of patients number from 2013 till now.	94
Figure 36:	Description of the total patients' compliance.	95
Figure 37:	Description of the patient still following or stopped KD and their compliance.....	96
Figure 38:	Comparison between pateints stopped KD and still on KD regarding compliance.....	97
Figure 39:	Description of the percentage of compliance of patients from 2013 till 2019.	99
Figure 40:	Frequency of GIT and Urinary complications	101
Figure 41:	Frequency of Dietetic complications of KD among patients.	101
Figure 42:	Comparison between the adaptive function of our patients before and after KD by using vineland test.	103
Figure 43:	Comparison of the frequency of convulsions before KD and after 3 months, 6 months, 12 months, 24 months and 36 months of KD.	105
Figure 44:	Comparison of severity of seizure according to Chalfont Score before and after KD.	107

List of Abbreviations

Abb.	Full term
AA	<i>Arachidonic acid</i>
ADEAF	<i>Autosomal dominant epilepsy with auditory features</i>
ADNFLE	<i>Autosomal-dominant nocturnal frontal lobe epilepsy</i>
AE	<i>Adverse events</i>
AED	<i>Antiepileptic drug</i>
BDH1	<i>BHB dehydrogenase</i>
BECTS	<i>Benign epilepsy with centrotemporal spikes</i>
BFNE	<i>Benign familial neonatal epilepsy</i>
BHB	<i>Beta – hydroxy- Butarate</i>
BMI	<i>Body mass index</i>
BNS	<i>Benign neonatal seizures</i>
CAE	<i>Childhood absence epilepsy</i>
CPT	<i>Carnitine palmitoyl ltransferase</i>
CSWS	<i>Continuous spike-and-wave during sleep</i>
DHA	<i>Docosahexanoic acid</i>
EEG	<i>Electroencephalogram</i>
EME	<i>Early myoclonic encephalopathy</i>
ESES	<i>Electrical Status Epilepticus in Sleep</i>
FIRES	<i>Febrile infection–related epilepsy syndrome</i>
FS	<i>Febrile seizures</i>
FS+	<i>Febrile seizures plus</i>
GA	<i>Gestational age</i>
GABA	<i>Gamma-amino butyric acid</i>
GI	<i>Glycemic index</i>
GLUT-1	<i>Glucose Transporter Protein 1</i>

List of Abbreviations cont...

Abb.	Full term
<i>Glut1DS</i>	<i>Glucose transporter protein 1 (Glut-1) deficiency syndrome</i>
<i>GSH</i>	<i>Glutathione</i>
<i>HMG-CoA</i>	<i>3-hydroxy-3-methylglutaryl CoA</i>
<i>ICIDH-2</i>	<i>International Classification of Functioning, Disability and Health</i>
<i>ILAE</i>	<i>International League against Epilepsy</i>
<i>JAE</i>	<i>Juvenile absence epilepsy</i>
<i>JME</i>	<i>Juvenile myoclonic epilepsy</i>
<i>KD</i>	<i>Ketogenic Diet</i>
<i>LCAD</i>	<i>Long-chain acyl dehydrogenase deficiency</i>
<i>LGIT</i>	<i>Low glycemic index treatment</i>
<i>LKS</i>	<i>Landau-Kleffner syndrome</i>
<i>LMIC</i>	<i>Low and middle-income countries</i>
<i>MAD</i>	<i>Modified Atkins diet</i>
<i>MCAD</i>	<i>Medium-chain acyl dehydrogenase deficiency</i>
<i>MCT</i>	<i>Medium-chain triglyceride</i>
<i>MEG</i>	<i>Magneto-encephalography</i>
<i>MEI</i>	<i>Myoclonic epilepsy in infancy</i>
<i>MRI</i>	<i>Magnetic resonance image</i>
<i>MTLE with HS</i>	<i>Mesial temporal lobe epilepsy with hippocampal sclerosis</i>
<i>NAD⁺</i>	<i>Nicotinamide adenine dinucleotide</i>
<i>NE</i>	<i>Norepinephrine</i>
<i>NPY</i>	<i>Neuropeptide-Y</i>
<i>NS</i>	<i>Non significant</i>
<i>PDH</i>	<i>Pyruvate dehydrogenase</i>

List of Abbreviations cont...

Abb.	Full term
<i>PDHD</i>	<i>Pyruvate dehydrogenase deficiency</i>
<i>PME</i>	<i>Progressive myoclonus epilepsies</i>
<i>PUFAs</i>	<i>Polyunsaturated fatty acids</i>
<i>ROS</i>	<i>Reactive oxygen species</i>
<i>S</i>	<i>Significant</i>
<i>SANAD</i>	<i>Standard versus New Antiepileptic Drugs</i>
<i>SCAD</i>	<i>Short-chain acyl dehydrogenase deficiency</i>
<i>SRS</i>	<i>Stereotactic radio-surgery</i>
<i>SSPE</i>	<i>Subacute sclerosing panencephalitis</i>
<i>UCPs</i>	<i>Uncoupling proteins</i>
<i>VNS</i>	<i>Vagus nerve stimulation</i>

INTRODUCTION

Epilepsy is a disorder that occur in about 1% of population and the onset of epilepsy in 60% of cases start in childhood (*Armeno et al., 2014*).

Epidemiological data indicate that 20-30% of patient will become refractory to therapy. Refractory epilepsy is defined as seizures that cannot be controlled with at least two first line antiepileptic drugs in adequate doses, as single or combined drug therapy (*Freeman et al., 2007*).

The ketogenic diet, a non-drug treatment had proven its effectiveness in treatment of epilepsy in children in the past decade especially in management of refractory epilepsy. The ketogenic diet is highly effective and reduce the incidence of seizures by 50% in a half of patient, and 90% in one third of patients (*Lee and Kossoff, 2011*).

The ketogenic diet is a high fat, low carbohydrate, adequate protein diet that cause ketosis and leads to metabolic state that resemble the fasting state (*Neal et al., 2008*). It works through multiple mechanisms that target a specific biochemical pathways linked to cell substrate (e.g, ion channel) and mediators responsible for neuronal hyperexcitability. It is also thought that the ketone bodies have direct anticonvulsant effect (*Rho and Neuroscil, 2015*).

The classical ketogenic diet is considered the treatment of choice for patient with a glucose transporter protein type 1 (GLUT1) deficiency or a pyruvate dehydrogenase (PDH) deficiency (*Nangia, 2012*).

Its use in Egypt has been started since 2011 and full publication on 2013 (*El-Rashidy et al., 2013*).

It is also important to exclude clinical condition for which the ketogenic diet is contraindicated (e.g, disorder of fatty acid oxidation, disorder of fatty acid transport, pyruvate carboxylase deficiency and porphyria) and assess risk factors that may complicate the use of ketogenic diet (e.g, gastroesophageal reflux (*Kossoff et al., 2009*).

The more common complications are metabolic acidosis and gastrointestinal manifestations, such as abdominal pain, nausea and vomiting with a risk of dehydration and hypoglycemia especially in patients who remain fasting for an extended period of time. Less common, but very important, effects because of their difficult management include eating disorders, such as loss of appetite, fluid rejection, and self-induced vomiting (*Ballaban et al., 1998*).

The ketogenic diet is a meal plan with an unbalanced intake of micro- and macronutrients; it may result in energy, protein, mineral and vitamin deficiency and excessive lipid intake, with a risk of unwanted side effects. However, its